Acute
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
Acute | 18 November 2011
-
New data presented on phase 3 trial Of ELIQUIS (apixaban) in the prevention of venous thromboembolism in patients with acute medical illness
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30.
Acute | 15 November 2011
-
FDA approves Shire’s FIRAZYR for acute attacks of hereditary angioedema
Shire plc announced that the US Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR (icatibant injection) for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. “Until now, HA…
Acute | 25 August 2011
-
GlobalData Forecasts Trends in Acute Ischemic Stroke Market to 2015
The industry report, “Acute Ischemic Stroke – Drug Pipeline Analysis and Market Forecasts to 2015†by GlobalData identifies the key trends that are shaping and driving the global Acute Ischemic Stroke (AIS) market. The global AIS market is …
Acute | 13 January 2010
-
Prasugrel, Clopidogrel head-to-head study
A new, pre-specified analysis of the landmark Phase III head-to-head Triton-Timi 38 study showed certain patients were 35% less likely to have a recurrent event (composite endpoint of heart attack, stroke or cardiovascular death) than those who took …
Acute | 25 August 2008
